|
|
- 2018
普萘洛尔对人黑色素瘤A375细胞增殖迁移和血管生成能力的影响及其机制研究
|
Abstract:
摘要 目的:探讨普萘洛尔对人黑色素瘤A375细胞增殖、迁移和促血管生成能力的影响和机制。方法:将1、5、10、20 μmol/L普萘洛尔作用于体外培养的A375细胞,MTT法检测普萘洛尔对A375细胞增殖能力的影响;细胞划痕实验测定普萘洛尔对A375细胞的迁移能力的影响;小管形成实验评估普萘洛尔对A375细胞促血管生成能力的影响;RT-PCR和 Western bolt分别检测普萘洛尔对A375细胞VEGF、MMP-9、CXCR4 mRNA 和蛋白表达的影响。结果:与对照组相比,普萘洛尔对A375细胞的增殖能力无显著性抑制,呈浓度依赖性抑制A375细胞的迁移能力和促血管生成能力,并且可显著性下调A375细胞中VEGF、MMP-9、CXCR4 mRNA 和蛋白的表达(P＜0.01) 。结论:普萘洛尔可能通过下调VEGF、MMP-9和CXCR4的表达发挥抑制A375细胞的迁移和促血管生成能力的作用
| [1] | 王晓妍,张祥成,张薇薇,等.VEGF-A和VEGF-C在皮肤恶性黑色素瘤表达的临床病理意义[J].现代生物医学进展,2013,13(26)∶5082-5086 |
| [2] | Tang J, Li Z, Lu L, et al. beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy[J]Semin Cancer Biol,2013,23(6)∶533-542 |
| [3] | 宋宁静,王晓楠,陈佳,等.MMP-2和MMP-9在皮肤恶性黑色素瘤中的表达及意义[J].中华全科医学,2011,09(8)∶1174-1174 |
| [4] | Dal Monte M, Casini G, Filippi L, et al.Functional involvement of beta3-adrenergic receptors in melanoma growth and vascularization [J].J Mol Med, 2013,91(12)∶1407-1419 |
| [5] | Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro [J]. Nature protocols, 2007,2(2)∶329-333 |
| [6] | Kryza D, Debordeaux F, Azema L, et al. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas [J]. PLoS One,2016,11(2)∶e0149387 |
| [7] | Roh MR, Eliades P, Gupta S, et al. Cutaneous melanoma in women [J]. Int J Womens Dermatol, 2017,16(3)∶S11-S15 |
| [8] | Coelho M, Soares-Silva C, Brandao D, et al.beta-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives [J]. J Cancer Res Clin Oncol, 2017, 143(2)∶275-291 |
| [9] | Wrobel LJ, Le Gal FA. Inhibition of human melanoma growth by a non-cardioselective beta-blocker [J]. J Invest Dermatol,2015, 135(2)∶525-531 |
| [10] | 韩永付, 韩新光. 27例口腔颌面部恶性黑色素瘤临床分析[J].口腔医学研究,2014(6)∶537-539 |
| [11] | Weberpals J, Jansen L, Carr Pr, et al. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis [J] . Cancer Treat Rev, 2016, 47∶1-11 |
| [12] | Childers Wk, Hollenbeak Cs, Cheriyath P. beta-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis [J]. Clinical breast cancer,2015;15(6)∶426-431 |
| [13] | Chen Y Z, Bai N, Bi J H, et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms[J]. Braz J Med Biol Res, 2017,50(12)∶e6138 |
| [14] | Lemeshow S, Sorensen Ht, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study [J].Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279 |
| [15] | Miao C, Liang C, Zhu J, et al. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis [J]. Oncotarget ,2017, 8(19)∶32309-32321 |
| [16] | De Giorgi V, Grazzini M, Gandini S, et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma[J].Arch Intern Med, 2011,171(8)∶779-781 |
| [17] | Lemeshow S, Sorensen Ht, Phillips G, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a populationbased nested case-control study[J]. Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279 |
| [18] | Pozzobon T, Goldoni G, Viola A, et al. CXCR4 signaling in health and disease [J]. Immunol Lett,2016 177∶6-15 |
| [19] | Mitchell B, Leone D, Feller K, et al. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 inprimary cutaneous melanoma-biomarkers of potential utility [J].Hum Pathol,2014,45(10)∶2094-2100 |
| [20] | Bi J, Li P, Li C, et al. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration [J].Tumor Biol,2016,37(3)∶4175-4182 |
